Alkermes plc (NASDAQ:ALKS) reported stronger-than-expected second-quarter results on Tuesday, driven by solid performance across its proprietary product lineup.
Shares rose 5.16% in pre-market trading after the announcement.
The biopharmaceutical firm posted adjusted earnings of $0.52 per share, well above the $0.36 consensus estimate. Revenue totaled $390.7 million, beating expectations of $347.16 million despite a 2.1% decline from $399.1 million in the same period last year.
Growth was seen across Alkermes’ three proprietary products, with total proprietary net sales rising 14% year-over-year to $307.2 million. LYBALVI revenue increased 18% to $84.3 million, ARISTADA climbed 18% to $101.3 million, and VIVITROL grew 9% to $121.7 million compared to Q2 2024.
“Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation,” said Richard Pops, Chief Executive Officer of Alkermes.
The company’s financial position remained strong, with cash, cash equivalents, and investments rising to $1.05 billion as of June 30, 2025, up from $916.2 million at the prior quarter-end.
Alkermes reaffirmed its 2025 financial guidance issued in February. It also noted positive topline data from the Vibrance-1 Phase 2 study of alixorexton for narcolepsy type 1, with detailed findings expected to be shared at the upcoming World Sleep Congress.
This strong quarterly showing reinforces Alkermes’ leadership in neuroscience as it advances its pipeline while generating steady revenue from its commercial portfolio.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.